Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Therapeutics Initiates Infectious Disease Programs\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oregon State Research Shows Hemp Compounds Prevent Coronavirus From Entering Human Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Avicanna","sponsor":"Applied Research Centre at Langara College","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna and Langara College Announce Cannabinoid-based Translational Research Collaboration and NSERC Grant","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Announces Closing of Non-Brokered Private Placement of Debenture Units","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Announces Closing of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"}]

    Find Clinical Drug Pipeline Developments & Deals for Cannabigerol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

    Menu

    Cannabigerol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Avicanna

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avicanna Announces Closing of Non-Brokered Private Placement

              Details:

              The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.

              Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: RHO Phyto

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $0.8 million Upfront Cash: Undisclosed

              Deal Type: Private Placement December 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Avicanna

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avicanna Announces Closing of Non-Brokered Private Placement of Debenture Units

              Details:

              The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.

              Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: RHO Phyto

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $1.4 million Upfront Cash: Undisclosed

              Deal Type: Private Placement August 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Avicanna

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avicanna and Langara College Announce Cannabinoid-based Translational Research Collaboration and NSERC Grant

              Details:

              The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.

              Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: RHO Phyto

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Applied Research Centre at Langara College

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Avicanna

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company

              Details:

              Through the license and supply agreement, the South American pharmaceutical company will license Avicanna’s intellectual property and supply finished pharmaceutical products starting initially with its proprietary 10% cannabidiol oral preparation, marketed under the RHO Phyto.

              Lead Product(s): Cannabidiol,Tetrahydrocannabinol,Cannabigerol

              Therapeutic Area: Neurology Product Name: Rho Phyto

              Highest Development Status: Phase IV Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $1.0 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

              Details:

              New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.

              Lead Product(s): Cannabigerol,Cannabidiol

              Therapeutic Area: Neurology Product Name: CBG:CBD

              Highest Development Status: Phase IV Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

              Details:

              Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.

              Lead Product(s): Cannabidiol,Cannabigerol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase IV Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Oregon State University

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oregon State Research Shows Hemp Compounds Prevent Coronavirus From Entering Human Cells

              Details:

              According to the research by Oregon state university Hemp Comound, Cannabigerolic Acid has a good safety profile in humans and are effective against variants of SARS-CoV-2 including variant.

              Lead Product(s): Cannabigerol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              180 Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules

              Details:

              HUM-234 was shown to prevent weight gain in mice fed a high fat diet, and importantly abrogated the development of fatty liver (steatosis), a condition clinically associated with multiple metabolic disorders, including diabetes and obesity and a precursor to liver fibrosis.

              Lead Product(s): Cannabigerol

              Therapeutic Area: Neurology Product Name: HUM-234

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              XPhyto

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              XPhyto Therapeutics Initiates Infectious Disease Programs

              Details:

              The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.

              Lead Product(s): Cannabigerol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY